About: Management of osteoarthritis during COVID‐19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of osteoarthritis during COVID‐19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Management of osteoarthritis during COVID‐19 pandemic
Creator	Banfi, Giuseppe Mangiavini, Laura Peretti, Giuseppe Brini, Anna De Girolamo, Laura Ragni, Enrico Viganò, Marco
Source	Medline; PMC
abstract	The pandemic spread of the new COVID‐19 coronavirus infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID‐19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit COVID‐19 pandemic may condition the treatment strategy of complex disorders, as osteoarthritis (OA). Importantly, OA is the most common age‐related joint disease affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID‐19 patients. OA patients often show a large array of concomitant pathologies such as diabetes, inflammation and cardiovascular diseases that are again shared with COVID‐19 patients and may therefore increase complications. Moreover, different OA treatments such as NSAIDs, paracetamol, corticosteroids, opioids or other molecules have a wide array of iatrogenic effects, potentially increasing COVID‐19 secondary infection incidence or complications. In this review we critically analyse the evidences on either negative or positive effect of drugs commonly used to manage OA in this particular scenario. This would provide orthopaedic surgeons at first, and physicians, pharmacologists and clinicians at general, a comprehensive description about the safety of the current pharmacological approaches and a decision making tool to treat their OA patients as the coronavirus pandemic continues.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1002/cpt.1910
bibo:pmid	32438454
has license	no-cc
sha1sum (hex)	20e66469604468201ab7d42a74fc0c5efd96a7c9
schema:url	https://doi.org/10.1002/cpt.1910
resource representing a document's title	Management of osteoarthritis during COVID‐19 pandemic
has PubMed Central identifier	PMC7280639
has PubMed identifier	32438454
schema:publication	Clin Pharmacol Ther
resource representing a document's body	covid:20e66469604468201ab7d42a74fc0c5efd96a7c9#body_text
is schema:about of	named entity 'pandemic' named entity 'emergency' named entity 'occasional' named entity 'infection' named entity 'strategy' named entity 'infection' named entity 'COVID-19 coronavirus' named entity 'NLRP3' named entity 'pneumonia' named entity 'rheumatoid arthritis' named entity 'mAbs' named entity 'intensive care' named entity 'constipation' named entity 'cardiovascular' named entity 'quality of life' named entity 'inflammation' named entity 'inflammatory cells' named entity 'adverse events' named entity 'Osteoarthritis' named entity 'SARS-CoV-2' named entity 'adverse events' named entity 'gastrointestinal' named entity 'liver diseases' named entity 'opioid' named entity 'morbidity' named entity 'NSAIDs' named entity 'co-morbidities' named entity 'mechanism of action' named entity 'immunosuppressive activity' named entity 'liver injury' named entity 'cytokines' named entity 'cytokine' named entity 'IL-1β' named entity 'immunosuppressive' named entity 'monoclonal antibody' named entity 'immediate-release' named entity 'TNFα' named entity 'chronic inflammatory' named entity 'inflammasome' named entity 'COVID' named entity 'COVID' named entity 'infection' named entity 'morbidity' named entity 'morbidity' named entity 'NSAIDs' named entity 'inflammatory cascade' named entity 'codeine' named entity 'analgesic' named entity 'TNFα' named entity 'TNFα' named entity 'COVID-19 pandemic' named entity 'serum' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'paracetamol' named entity 'orthopaedic surgeons' named entity 'Comorbidities' named entity 'NSAIDs' named entity 'cardiovascular diseases' named entity 'osteoporosis' named entity 'lung diseases' named entity 'olfactory' named entity 'morbidity' named entity 'Synovitis' named entity 'TNFα' named entity 'Corticosteroids' named entity 'synovium' named entity 'metalloproteases' named entity 'proinflammatory cytokines' named entity 'age-related' named entity 'transdermal' named entity 'inflammation' named entity 'Disease-modifying' named entity 'risk factor' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software